<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02731001</url>
  </required_header>
  <id_info>
    <org_study_id>STR - PRONTOX - 2014</org_study_id>
    <nct_id>NCT02731001</nct_id>
  </id_info>
  <brief_title>Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer</brief_title>
  <acronym>PRONTOX</acronym>
  <official_title>Proton Therapy to Reduce Acute Normal Tissue Toxicity in Locally Advanced Non-small-cell Lung Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Technische Universit채t Dresden</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>German Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Radiation Research in Oncology Dresden/Heidelberg</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Technische Universit채t Dresden</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aims of the study are to reduce acute radiation induced side effects, i.e. pneumonitis&#xD;
      and esophagitis grade II or higher by the use of proton therapy compared to photon&#xD;
      radiotherapy of equal total dose. Secondary endpoints include evaluation of quality of life,&#xD;
      loco-regional control, survival and late radiation induced side effects.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients in this trial undergo primary radiochemotherapy for locally advanced NSCLC. As early&#xD;
      and intermediate late effects of radiotherapy do not only hamper quality of life but can, in&#xD;
      the case of radiation induced pneumonitis, be potentially lethal, a reduction of these side&#xD;
      effects is desirable. Patients in this trial are 1:1 randomised to intensity modulated&#xD;
      radiotherapy with photons or proton therapy. The primary aim of the study is to show a&#xD;
      decrease of pneumonitis and or esophagitis grade 2 or higher by proton therapy. The observed&#xD;
      incidence of both these side effects is 39% with photon therapy. The estimated incidence with&#xD;
      proton therapy is around 12 %. Simultaneous chemotherapy will be applied to current clinical&#xD;
      standards.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2016</start_date>
  <completion_date type="Anticipated">December 2025</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Occurrence of acute and intermediate radiation induced side effects</measure>
    <time_frame>no later than six months after end of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">98</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>Proton therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients within the proton arm will receive 66 Gy(RBE) delivered with 6 fractions per week.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Photon therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients within the photon arm will be treated by intensity modulated radiotherapy with 6 fractions per week to a total dose of 66 Gy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Proton therapy</intervention_name>
    <arm_group_label>Proton therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Photon therapy</intervention_name>
    <arm_group_label>Photon therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  NSCLC (confirmed by cytology or histology) staged UICC IIIA or IIIB or UICC II if the&#xD;
             patient declines surgery&#xD;
&#xD;
          -  no distant metastases (M1)&#xD;
&#xD;
          -  patient' age between 18 and 70 years&#xD;
&#xD;
          -  Patient medically suited for primary radiochemotherapy with curative intent&#xD;
&#xD;
          -  signed declaration of informed consent&#xD;
&#xD;
          -  adequate compliance for treatment and clinical follow up&#xD;
&#xD;
          -  adequate contraception during and after therapy if indicated&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Participation in other interventional trial&#xD;
&#xD;
          -  T1 or T2 N0 tumours that are candidates for stereotactic radiotherapy&#xD;
&#xD;
          -  relevant neurological or psychiatric disorders that hinder treatment, follow-up or&#xD;
             understanding of the procedures&#xD;
&#xD;
          -  pregnant or breastfeeding women&#xD;
&#xD;
          -  prior thoracic radiotherapy&#xD;
&#xD;
          -  history of other malignancies during the last 5 years (exceptions can be made for&#xD;
             tumours with excellent outcome)&#xD;
&#xD;
          -  weight loss greater than 15% before therapy&#xD;
&#xD;
          -  serological alterations (liver, kidney) prohibiting application of simultaneous&#xD;
             chemotherapy&#xD;
&#xD;
          -  respiratory motion of the tumour &gt; 10 mm (evaluated by 4D CT), also when methods for&#xD;
             motion reduction (abdominal compression) are used&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Esther Troost, Prof.</last_name>
    <role>Study Chair</role>
    <affiliation>Technische Universit채t Dresden, German Cancer Consortium, Helmholtz-Zentrum Dresden - Rossendorf</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Esther Troost, Prof.</last_name>
    <phone>+49 351 458 2238</phone>
    <email>str.studien@uniklinikum-dresden.de</email>
  </overall_contact>
  <location>
    <facility>
      <name>Department of Radiotherapy and Radiation Oncology</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Esther Troost, Prof.</last_name>
      <phone>+49 351 458 2238</phone>
      <email>str.studien@uniklinikum-dresden.de</email>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 1, 2016</study_first_submitted>
  <study_first_submitted_qc>April 1, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 7, 2016</study_first_posted>
  <last_update_submitted>August 18, 2021</last_update_submitted>
  <last_update_submitted_qc>August 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 19, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Technische Universit채t Dresden</investigator_affiliation>
    <investigator_full_name>Prof. Esther Troost</investigator_full_name>
    <investigator_title>Prof. Esther Troost</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

